Equity Overview
Price & Market Data
Price: $7.00
Daily Change: -$0.27 / 3.86%
Daily Range: $7.00 - $7.31
Market Cap: $888,811,520
Daily Volume: 1,124,861
Performance Metrics
1 Week: -1.42%
1 Month: 18.31%
3 Months: 9.61%
6 Months: 73.40%
1 Year: 179.7%
YTD: 77.18%
Company Details
Employees: 26
Sector: Health technology
Industry: Biotechnology
Country:
Details
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.